ACADIA Pharmaceuticals Initiates Phase 3 Pivotal Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder
Go back to ACADIA Pharmaceuticals Initiates Phase 3 Pivotal Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 21.09 -0.3 (1.4%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $21.39 | 52 Week High | $42.49 | |||
| Open | $21.49 | 52 Week Low | $16.64 | |||
| Day High | $21.55 | P/E | N/A | |||
| Day Low | $21.05 | EPS | $-0.42 | |||
| Volume | 753,938 | |||||
